Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8019850 | 0.97 | MAOA (0.35) | MAOAMAOBCA14CA12CA1 | |
| SCHEMBL13427909 | 0.97 | MAOA (0.36) | MAOAMAOBCA14CA12CA1 | |
| SCHEMBL440219 | 0.94 | MAOA (0.35) | MAOAMAOBCA14CA12CA1 | |
| SCHEMBL6536011 | 0.93 | MAOA (0.36) | MAOAMAOBCA14CA12CA1 | |
| SCHEMBL22234380 | 0.91 | MAOA (0.33) | MAOAMAOBCA14CA12CA1 | |
| SCHEMBL23130694 | 0.90 | NR1D1 (0.34) | MAOAMAOBCA14CA12CA1 | |
| SCHEMBL18636575 | 0.89 | MAOA (0.35) | MAOAMAOB | |
| SCHEMBL23130697 | 0.88 | TDP1 (0.34) | MAOAMAOBCA14CA12CA1 | |
| SCHEMBL7745466 | 0.88 | NR1D1 (0.34) | MAOAMAOBCA14CA12CA1 | |
| SCHEMBL25477299 | 0.88 | MAOA (0.32) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233714-A1 | NOVEL GADOLINIUM-BASED COMPOUND, METHOD FOR PRODUCING SAME, AND MRI CONTRAST AGENT CONTAINING SAME | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-07-27 | — | — | US | disclosed |
| WO-2021198229-A1 | SELECTIVE GIP RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING AND THERAPY PURPOSES | ANTAROS MEDICAL AB (SE) | 2021-10-07 | — | — | WO | disclosed |
| EP-3389697-B1 | SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES | ANTAROS MEDICAL AB (SE) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019182395-A1 | COMPOUND HAVING NOVEL STRUCTURE, ANTI-INFLAMMATORY AGENT COMPRISING SAME, AND CYCLOOXYGENASE-2 INHIBITOR COMPRISING SAME | 장용민 | 2019-09-26 | — | — | WO | disclosed |
| WO-2017102613-A1 | SELECTIVE GLUCAGON RECEPTOR AGONISTS COMPRISING A CHELATING MOIETY FOR IMAGING PURPOSES | SANOFI (FR) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233714-A1 | NOVEL GADOLINIUM-BASED COMPOUND, METHOD FOR PRODUCING SAME, AND MRI CONTRAST AGENT CONTAINING SAME | GLRX3, GMNN, GRM2 | MAOA 2779/4885MAOB 2634/4885CA14 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.